MIDDLE EAST PHARMACEUTICAL INDUSTRIES COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 152 SAR | -1.94% |
|
+4.83% | 0.00% |
| May. 06 | Avalon Pharma Secures Regulatory Nod for Second Production Facility in Saudi Arabia | MT |
| Mar. 25 | Saudi Exchange Adds Seven Companies to Certain Market Indices | MT |
Valuation
| Fiscal Period: December | 2024 | 2025 | 2026 |
|---|---|---|---|
| Capitalization 1 | 3,040 | - | - |
| Enterprise Value (EV) 1 | 3,040 | 3,040 | 3,040 |
| P/E ratio | - | - | - |
| Yield | 1.25% | 1.45% | - |
| Capitalization / Revenue | 8.13 x | 7 x | 6.12 x |
| EV / Revenue | 8.13 x | 7 x | 6.12 x |
| EV / EBITDA | 28.1 x | 24.3 x | - |
| EV / FCF | 65.8 x | 87.1 x | 87.9 x |
| FCF Yield | 1.52% | 1.15% | 1.14% |
| Price to Book | - | - | - |
| Nbr of stocks (in thousands) | 20,000 | - | - |
| Reference price 2 | 152.0 | 152.0 | 152.0 |
| Announcement Date | - | - | - |
1SAR in Million2SAR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 338.4 | 374 | 434 | 497 |
| EBITDA 1 | - | 90.18 | 108 | 125 | - |
| EBIT 1 | - | 78.25 | 92 | 106 | 119 |
| Operating Margin | - | 23.12% | 24.6% | 24.42% | 23.94% |
| Earnings before Tax (EBT) | - | - | - | - | - |
| Net income | 59.45 | - | - | - | - |
| Net margin | - | - | - | - | - |
| EPS | 2.970 | - | - | - | - |
| Free Cash Flow 1 | - | - | 46.2 | 34.9 | 34.6 |
| FCF margin | - | - | 12.35% | 8.04% | 6.96% |
| FCF Conversion (EBITDA) | - | - | 42.78% | 27.92% | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share 2 | - | - | 1.900 | 2.200 | - |
| Announcement Date | 1/7/24 | 3/25/24 | - | - | - |
1SAR in Million2SAR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2024 Q1 |
|---|---|
| Net sales 1 | 62 |
| EBITDA | - |
| EBIT | - |
| Operating Margin | - |
| Earnings before Tax (EBT) | - |
| Net income | - |
| Net margin | - |
| EPS | - |
| Dividend per Share | - |
| Announcement Date | - |
1SAR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | - | 46.2 | 34.9 | 34.6 |
| ROE (net income / shareholders' equity) | - | 22.4% | 22% | 22% | - |
| ROA (Net income/ Total Assets) | - | 14.8% | 15% | 15.5% | 15.7% |
| Assets | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | - | 20.8 | 29.9 | 34.7 | 49.7 |
| Capex / Sales | - | 6.16% | 7.99% | 8% | 10% |
| Announcement Date | 1/7/24 | 3/25/24 | - | - | - |
1SAR in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
SELL
Number of Analysts
1
Last Close Price
152
SAR
Average target price
107
SAR
Spread / Average Target
-29.61%
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 827M | |
| +20.85% | 43.57B | |
| +22.08% | 22.7B | |
| +16.41% | 14.32B | |
| +11.44% | 13.42B | |
| +45.51% | 11.83B | |
| -9.12% | 6.98B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +12.41% | 5.51B |
- Stock Market
- Equities
- 4016 Stock
- Financials Middle East Pharmaceutical Industries Company